ArticleAmerican heart journal2021

Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study.

Warren H Capell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.